- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02443233
Evaluation of Paternal, Maternal and Obstetric Factors Leading to the Hepatitis B Immunization Failure in Hong Kong
June 9, 2017 updated by: The University of Hong Kong
Globally, hepatitis B virus (HBV) infection is the most common form of chronic hepatitis. There are still a lot of uncertainties on how infants acquired HBV leading to the development of chronic HBV infection despite active and passive immunoprophylaxis. The investigators would like to carry out a prospective study to answer the following questions:
- the paternal, maternal and obstetric factors leading to immunoprophylaxis failure
- the prevalence of immunoprophylaxis failure in Hong Kong
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
750
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Hong Kong
-
Hong Kong, Hong Kong, China, 852
- Department of Obstetrics and Gynaecology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Maternal and paternal hepatitis B carrier
Description
Inclusion Criteria:
- All women age ≥ 18 years
- Maternal or paternal hepatitis B carrier
Exclusion Criteria:
- Couples will be excluded if female partners of paternal hepatitis B carrier were occult carrier
- Plan to deliver in other units
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Maternal hepatitis B carrier
|
|
Paternal hepatitis B carrier
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The effect of high maternal viral load on immunoprophylaxis failure, using 10^6 copies/ml as cut-off
Time Frame: Infants' blood for HbsAg at 9-12 months old
|
Infants' blood for HbsAg at 9-12 months old
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Ka Wang Cheung, The University of Hong Kong
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2014
Primary Completion (Actual)
December 1, 2016
Study Completion (Actual)
December 1, 2016
Study Registration Dates
First Submitted
April 28, 2015
First Submitted That Met QC Criteria
May 10, 2015
First Posted (Estimate)
May 13, 2015
Study Record Updates
Last Update Posted (Actual)
June 12, 2017
Last Update Submitted That Met QC Criteria
June 9, 2017
Last Verified
June 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UW 13-270
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis B Infection
-
GigaGen, Inc.RecruitingHepatitis B Virus InfectionUnited States, Australia, Hong Kong, South Korea
-
Enanta Pharmaceuticals, IncTerminatedChronic Hepatitis B Virus InfectionNew Zealand
-
Yangshengtang Co., LtdTerminatedChronic Hepatitis B Virus InfectionAustralia
-
Fondazione Epatocentro TicinoRecruitingChronic HBV InfectionSwitzerland
-
Hoffmann-La RocheTerminatedHepatitis B Virus InfectionUnited Kingdom, Hong Kong, Korea, Republic of, Taiwan, Poland, Bulgaria, New Zealand
-
Qiu LiRecruitingHepatitis b Virus InfectionChina
-
Beijing Kawin Technology Share-Holding Co., Ltd.CompletedChronic Hepatitis B Virus InfectionChina
-
Enanta Pharmaceuticals, IncPharmaceutical Research AssociatesCompletedChronic HBV InfectionUnited States, Canada
-
Sun Yat-sen UniversityRecruitingChronic Hepatitis B Virus InfectionChina
-
Brii Biosciences LimitedVir Biotechnology, Inc.Active, not recruitingChronic Hepatitis B Virus InfectionSingapore, Thailand, Australia, China, South Korea